dc.contributor.author | Mangino, M | |
dc.contributor.author | Cecelja, M | |
dc.contributor.author | Menni, C | |
dc.contributor.author | Tsai, P-C | |
dc.contributor.author | Yuan, W | |
dc.contributor.author | Small, K | |
dc.contributor.author | Bell, J | |
dc.contributor.author | Mitchell, GF | |
dc.contributor.author | Chowienczyk, P | |
dc.contributor.author | Spector, TD | |
dc.date.accessioned | 2018-07-05T09:12:13Z | |
dc.date.issued | 2016-01-01 | |
dc.identifier | http://journals.lww.com/jhypertension/pages/articleviewer.aspx?year=2016&issue=01000&article=00013&type=abstract | |
dc.identifier.citation | JOURNAL OF HYPERTENSION, 2016, 34 (1), pp. 79 - 87 | |
dc.identifier.issn | 0263-6352 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1985 | |
dc.description.abstract | Background: Carotid-femoral pulse wave velocity (PWV) is an important measure of arterial stiffness, which is an independent predictor of cardiovascular morbidity and mortality. In this study, we used an integrated genetic, epigenetic and transcriptomics approach to uncover novel molecular mechanisms contributing to PWV. Methods and results: We measured PWV in 1505 healthy twins of European descendent. A genomewide association analysis was performed using standardized residual of the inverse of PWV. We identified one single-nucleotide polymorphism (rs7164338) in the calcium and integrin-binding protein-2 (CIB2) gene on chromosome 15q25.1 associated with PWV [beta = -0.359, standard error (SE) = 0.07, P = 4.8 x 10(-8)]. The same variant was also associated with increased CIB2 expression in leucocytes (beta = 0.034, SE = 0.008, P = 4.95 x 10(-5)) and skin (beta = 0.072, SE = 0.01, P = 2.35 x 10(-9)) and with hypomethylation of the gene promoter (beta = -.899, SE = 0.098, P = 3.63 x 10(-20)). Conclusion: Our data indicate that reduced methylation of the CIB2 promoter in individuals carrying rs7164338 may lead to increased CIB2 expression. Given that CIB2 is thought to regulate intracellular calcium levels, an increase in protein levels may prevent the accumulation of serum calcium and phosphate, ultimately slowing down the process of vascular calcification. This study shows the power of integrating multiple omics to discover novel cardiovascular mechanisms. | |
dc.format.extent | 79 - 87 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Ovid Technologies (Wolters Kluwer Health) | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | arterial stiffness arteriosclerosis association calcium and integrin-binding protein-2 pulse wave velocity vascular calcification GENOME-WIDE ASSOCIATION CHRONIC KIDNEY-DISEASE ALL-CAUSE MORTALITY ARTERIAL STIFFNESS CARDIOVASCULAR EVENTS BLOOD-PRESSURE RACIAL-DIFFERENCES AORTIC STIFFNESS CALCIFICATION RISK | |
dc.title | Integrated multiomics approach identifies calcium and integrin-binding protein-2 as a novel gene for pulse wave velocity | |
dc.type | Journal Article | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2016 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | JOURNAL OF HYPERTENSION | |
pubs.issue | 1 | |
pubs.notes | ISI Document Delivery No.: DK9CT Times Cited: 1 Cited Reference Count: 47 Mangino, Massimo Cecelja, Marina Menni, Cristina Tsai, Pei-Chien Yuan, Wei Small, Kerrin Bell, Jordana Mitchell, Gary F. Consortium, AortaGen Chowienczyk, Phillip Spector, Tim D. Wellcome Trust; European Community's Seventh Framework Programme (FP7); National Institute for Health Research (NIHR) BioResource Clinical Research Facility; Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London The study was funded by the Wellcome Trust; European Community's Seventh Framework Programme (FP7/2007-2013). The study also received support from the National Institute for Health Research (NIHR) BioResource Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. SNP genotyping was performed by The Wellcome Trust Sanger Institute and National Eye Institute via NIH/CIDR. 1 LIPPINCOTT WILLIAMS & WILKINS PHILADELPHIA J HYPERTENS public Background: Carotid-femoral pulse wave velocity (PWV) is an important measure of arterial stiffness, which is an independent predictor of cardiovascular morbidity and mortality. In this study, we used an integrated genetic, epigenetic and transcriptomics approach to uncover novel molecular mechanisms contributing to PWV. Methods and results: We measured PWV in 1505 healthy twins of European descendent. A genomewide association analysis was performed using standardized residual of the inverse of PWV. We identified one single-nucleotide polymorphism (rs7164338) in the calcium and integrin-binding protein-2 (CIB2) gene on chromosome 15q25.1 associated with PWV [beta = -0.359, standard error (SE) = 0.07, P = 4.8 x 10(-8)]. The same variant was also associated with increased CIB2 expression in leucocytes (beta = 0.034, SE = 0.008, P = 4.95 x 10(-5)) and skin (beta = 0.072, SE = 0.01, P = 2.35 x 10(-9)) and with hypomethylation of the gene promoter (beta = -.899, SE = 0.098, P = 3.63 x 10(-20)). Conclusion: Our data indicate that reduced methylation of the CIB2 promoter in individuals carrying rs7164338 may lead to increased CIB2 expression. Given that CIB2 is thought to regulate intracellular calcium levels, an increase in protein levels may prevent the accumulation of serum calcium and phosphate, ultimately slowing down the process of vascular calcification. This study shows the power of integrating multiple omics to discover novel cardiovascular mechanisms. | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Cancer Biomarkers | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Cancer Biomarkers | |
pubs.volume | 34 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Cancer Biomarkers | |
dc.contributor.icrauthor | Yuan, Wei | |